A study attempting to characterize the true preventability of venous thromboembolism determined that financial penalties based on the total number of patients who suffer blood clots in the lung or leg may be unfairly imposed.
A study attempting to characterize the true preventability of venous thromboembolism (VTE) determined that financial penalties based on the total number of patients who suffer blood clots in the lung or leg may be unfairly imposed.
Researchers with Johns Hopkins University School of Medicine reviewed 128 medical case histories and came to the conclusion that the current pay-for-performance system is a problem. Elliott R. Haut, MD, PhD, an associate professor of surgery at the Johns Hopkins University School of Medicine, explained that even when hospitals do everything they can to prevent VTE, they can still be penalized for patients who develop blood clots.
Nearly half of VTE events identified by the Maryland state program were not truly preventable, he said.
“We know we’re not going to get the VTE rate to zero, but my goal is to have every single one of these events—when they happen—occur when the patient receives best-practice, defect-free care,” Dr Haut said in a statement.
If the findings hold true across the state of Maryland and the rest of the country, hospitals may be penalized millions of dollars through inappropriate fines.
In a research letter published in JAMA Surgery, Dr Haut and his colleagues noted that even with the use of blood thinners and other best practices, some patients will still develop clots. Meanwhile, government regulatory agencies and health insurers are increasingly tracking the number of patients who develop blood clots and imposing financial penalties.
The researchers argue that instead of looking solely at total numbers of patients who develop clots, a better measure would be to track whether patients at risk for clots were appropriately prescribed and given clot-preventing medications.
“To reduce preventable harm, policymakers need to re-evaluate how they penalize hospitals and improve the measures they use to assess VTE prevention performance,” Dr Haut said. “In addition, clinicians need to ensure that patients receive all prescribed preventive therapies.”
What We’re Reading: FDA Approves UTI Antibiotic; Ozempic, Wegovy Price Investigation; US Births Fall
April 25th 2024The FDA recently approved an antibiotic for the treatment of urinary tract infections (UTIs) in women; a Senate committee recently launched an investigation into the prices of Novo Nordisk’s diabetes and weight loss drugs; US births fell last year, resuming a national slide after a previous increase during the pandemic.
Read More
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
What We’re Reading: Abortion Privacy Rules; Alzheimer Drug Hurdles; Nursing Home Staffing Overhaul
April 23rd 2024New health privacy rules aim to protect patients and providers in an evolving abortion landscape; some physicians express concerns about efficacy, risks, and entrenched beliefs in treating Alzheimer disease; CMS addresses longstanding staffing deficits in nursing homes.
Read More
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More